Skip to main content
Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences 2/2010

01.03.2010 | Original article

Systematic review: photodynamic therapy for unresectable cholangiocarcinoma

verfasst von: Fei Gao, Yu Bai, Shu-Ren Ma, Feng Liu, Zhao-Shen Li

Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Palliative therapies for unresectable cholangiocarcinoma such as stent, radiotherapy and chemotherapy have generally been disappointing. Therefore, it is necessary to find a new approach to fighting the disease. Several published clinical trials have reported the therapeutic effect of photodynamic therapy (PDT) for unresectable cholangiocarcinoma.

Objective

To assess the safety and efficacy of photodynamic therapy for patients with unresectable cholangiocarcinoma.

Methods

Relevant studies were retrieved from the Medline, Current Contents, Embase, and Cochrane Library databases. Inclusion of papers was determined by using a predetermined protocol; independent assessments and the final consensus decision were performed by two independent reviewers. Acceptable study designs included randomized controlled trials (RCTs), controlled clinical trials (CCTs), case studies, and case reports. Twenty studies met the inclusion criteria, and were tabulated and critically appraised in terms of characteristics, methods, outcomes, and complications.

Results

Twenty studies were included. The quality of the available evidence was low to moderate with the majority of studies being uncontrolled before and after design and thus limited by the retrospective nature of much of the available data. After PDT, it is reported that bilirubin serum levels declined, quality of life improved and survival time increased in most of the patients. At the same time, there were few complications.

Conclusions

Based on currently available evidence, PDT was safe and effective for patients with inoperable cholangiocarcinoma.
Literatur
1.
Zurück zum Zitat Jarnagin WR, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–17 (discussion 517–9).CrossRefPubMed Jarnagin WR, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–17 (discussion 517–9).CrossRefPubMed
2.
Zurück zum Zitat Todoroki T, et al. Treatment strategy for patients with middle and lower third bile duct cancer. Br J Surg. 2001;88(3):364–70.CrossRefPubMed Todoroki T, et al. Treatment strategy for patients with middle and lower third bile duct cancer. Br J Surg. 2001;88(3):364–70.CrossRefPubMed
3.
Zurück zum Zitat Sagawa N, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today. 2005;35(7):548–52.CrossRefPubMed Sagawa N, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today. 2005;35(7):548–52.CrossRefPubMed
4.
Zurück zum Zitat Pitt HA, et al. Perihilar cholangiocarcinoma postoperative radiotherapy does not improve survival. Ann Surg. 1995;221(6):788–97 (discussion 797–98).CrossRefPubMed Pitt HA, et al. Perihilar cholangiocarcinoma postoperative radiotherapy does not improve survival. Ann Surg. 1995;221(6):788–97 (discussion 797–98).CrossRefPubMed
5.
Zurück zum Zitat Figueras J, et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl. 2000;6(6):786–94.PubMed Figueras J, et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl. 2000;6(6):786–94.PubMed
6.
Zurück zum Zitat Takada T, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–95.CrossRefPubMed Takada T, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–95.CrossRefPubMed
7.
Zurück zum Zitat Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. 2000;47(33):644–9.PubMed Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. 2000;47(33):644–9.PubMed
8.
Zurück zum Zitat Kaassis M, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc. 2003;57(2):178–82.CrossRefPubMed Kaassis M, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc. 2003;57(2):178–82.CrossRefPubMed
9.
Zurück zum Zitat Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc. 1998;47(5):354–62.CrossRefPubMed Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc. 1998;47(5):354–62.CrossRefPubMed
10.
Zurück zum Zitat Prat F, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut. 1998;42(1):76–80.PubMedCrossRef Prat F, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut. 1998;42(1):76–80.PubMedCrossRef
11.
Zurück zum Zitat Shinchi H, et al. Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol. 2000;75(2):89–94.CrossRefPubMed Shinchi H, et al. Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol. 2000;75(2):89–94.CrossRefPubMed
12.
Zurück zum Zitat Bowling TE, et al. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut. 1996;39(6):852–5.CrossRefPubMed Bowling TE, et al. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut. 1996;39(6):852–5.CrossRefPubMed
13.
Zurück zum Zitat Rao S, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005;92(9):1650–4.CrossRefPubMed Rao S, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005;92(9):1650–4.CrossRefPubMed
14.
Zurück zum Zitat Glimelius B, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7(6):593–600.PubMed Glimelius B, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7(6):593–600.PubMed
15.
Zurück zum Zitat Abels C. Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). Photochem Photobiol Sci. 2004;3(8):765–71.CrossRefPubMed Abels C. Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). Photochem Photobiol Sci. 2004;3(8):765–71.CrossRefPubMed
16.
17.
Zurück zum Zitat Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49(1):1–7.CrossRefPubMed Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49(1):1–7.CrossRefPubMed
18.
Zurück zum Zitat Ortner MA, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology. 1998;114(3):536–42.CrossRefPubMed Ortner MA, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology. 1998;114(3):536–42.CrossRefPubMed
19.
Zurück zum Zitat Likier HM, Levine JG, Lightdale CJ. Photodynamic therapy for completely obstructing esophageal carcinoma. Gastrointest Endosc. 1991;37(1):75–8.CrossRefPubMed Likier HM, Levine JG, Lightdale CJ. Photodynamic therapy for completely obstructing esophageal carcinoma. Gastrointest Endosc. 1991;37(1):75–8.CrossRefPubMed
20.
Zurück zum Zitat Javaid B, Watt P, Krasner N. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study. Lasers Med Sci. 2002;17(1):51–6.CrossRefPubMed Javaid B, Watt P, Krasner N. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study. Lasers Med Sci. 2002;17(1):51–6.CrossRefPubMed
21.
Zurück zum Zitat McCaughan JS Jr, et al. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg. 1991;126(1):111–3.PubMed McCaughan JS Jr, et al. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg. 1991;126(1):111–3.PubMed
22.
Zurück zum Zitat Moher D, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–13.CrossRefPubMed Moher D, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–13.CrossRefPubMed
23.
Zurück zum Zitat Schulz KF, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama. 1995;273(5):408–12.CrossRefPubMed Schulz KF, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama. 1995;273(5):408–12.CrossRefPubMed
24.
Zurück zum Zitat Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.5 (updated May 2005). In: The Cochrane library. Chichester: Wiley; 2005 (Issue 3). Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.5 (updated May 2005). In: The Cochrane library. Chichester: Wiley; 2005 (Issue 3).
25.
Zurück zum Zitat Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191–4.CrossRefPubMed Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191–4.CrossRefPubMed
26.
Zurück zum Zitat Zoepf T, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100(11):2426–30.CrossRefPubMed Zoepf T, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100(11):2426–30.CrossRefPubMed
27.
Zurück zum Zitat Ortner ME, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125(5):1355–63.CrossRefPubMed Ortner ME, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125(5):1355–63.CrossRefPubMed
28.
Zurück zum Zitat Kahaleh M, et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol. 2008;6(3):290–7.CrossRefPubMed Kahaleh M, et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol. 2008;6(3):290–7.CrossRefPubMed
29.
Zurück zum Zitat Witzigmann H, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244(2):230–9.CrossRefPubMed Witzigmann H, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244(2):230–9.CrossRefPubMed
30.
Zurück zum Zitat Dumoulin FL, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc. 2003;57(7):860–7.CrossRefPubMed Dumoulin FL, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc. 2003;57(7):860–7.CrossRefPubMed
31.
Zurück zum Zitat Prasad GA, et al. Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. Clin Gastroenterol Hepatol. 2007;5(6):743–8.CrossRefPubMed Prasad GA, et al. Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. Clin Gastroenterol Hepatol. 2007;5(6):743–8.CrossRefPubMed
32.
Zurück zum Zitat Pereira SP, et al. Photodynamic therapy of malignant biliary strictures using meso-tetrahydroxyphenylchlorin. Eur J Gastroenterol Hepatol. 2007;19(6):479–85.CrossRefPubMed Pereira SP, et al. Photodynamic therapy of malignant biliary strictures using meso-tetrahydroxyphenylchlorin. Eur J Gastroenterol Hepatol. 2007;19(6):479–85.CrossRefPubMed
33.
Zurück zum Zitat Shim CS, et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy. 2005;37(5):425–33.CrossRefPubMed Shim CS, et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy. 2005;37(5):425–33.CrossRefPubMed
34.
Zurück zum Zitat Harewood GC, et al. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol. 2005;20(3):415–20.CrossRefPubMed Harewood GC, et al. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol. 2005;20(3):415–20.CrossRefPubMed
35.
Zurück zum Zitat Wiedmann M, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc. 2004;60(1):68–75.CrossRefPubMed Wiedmann M, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc. 2004;60(1):68–75.CrossRefPubMed
36.
Zurück zum Zitat Nanashima A, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol. 2004;39(11):1095–101.CrossRefPubMed Nanashima A, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol. 2004;39(11):1095–101.CrossRefPubMed
37.
Zurück zum Zitat Suzuki S, et al. Photodynamic therapy for malignant biliary obstruction: a case series. Endoscopy. 2004;36(1):83–7.CrossRefPubMed Suzuki S, et al. Photodynamic therapy for malignant biliary obstruction: a case series. Endoscopy. 2004;36(1):83–7.CrossRefPubMed
38.
Zurück zum Zitat Wiedmann M, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer. 2003;97(11):2783–90.CrossRefPubMed Wiedmann M, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer. 2003;97(11):2783–90.CrossRefPubMed
39.
Zurück zum Zitat Zoepf T, et al. Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc. 2001;54(6):763–6.CrossRefPubMed Zoepf T, et al. Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc. 2001;54(6):763–6.CrossRefPubMed
40.
Zurück zum Zitat Zoepf T, et al. Photodynamic therapy for palliation of nonresectable bile duct cancer—preliminary results with a new diode laser system. Am J Gastroenterol. 2001;96(7):2093–7.PubMed Zoepf T, et al. Photodynamic therapy for palliation of nonresectable bile duct cancer—preliminary results with a new diode laser system. Am J Gastroenterol. 2001;96(7):2093–7.PubMed
41.
Zurück zum Zitat Rumalla A, et al. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc. 2001;53(4):500–4.CrossRefPubMed Rumalla A, et al. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc. 2001;53(4):500–4.CrossRefPubMed
42.
Zurück zum Zitat Berr F, et al. Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma. J Hepatol. 2000;32(2):352–7.CrossRefPubMed Berr F, et al. Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma. J Hepatol. 2000;32(2):352–7.CrossRefPubMed
43.
Zurück zum Zitat Berr F, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology. 2000;31(2):291–8.CrossRefPubMed Berr F, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology. 2000;31(2):291–8.CrossRefPubMed
Metadaten
Titel
Systematic review: photodynamic therapy for unresectable cholangiocarcinoma
verfasst von
Fei Gao
Yu Bai
Shu-Ren Ma
Feng Liu
Zhao-Shen Li
Publikationsdatum
01.03.2010
Verlag
Springer Japan
Erschienen in
Journal of Hepato-Biliary-Pancreatic Sciences / Ausgabe 2/2010
Print ISSN: 1868-6974
Elektronische ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-009-0109-3

Weitere Artikel der Ausgabe 2/2010

Journal of Hepato-Biliary-Pancreatic Sciences 2/2010 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.